A vaccination strategy against Chlamydia and other sexually transmitted diseases
- Technology Benefits
- § By design, only a fragment of the Chlamydia protein is included in the protein fusion so that expression and purification steps are easier, and less expensive than for the whole protein. § Careful choice of the Chlamydia protein fragment, and fusion to the Neisseria protein, vastly increase likelihood of a robust immune response and an effective vaccine.
- Detailed Technology Description
- In the US alone, over 1 million cases of Chlamydia are reported each year. Increasing prevalence of Multiple-Drug Resistant Chlamydia is rendering antibiotic treatment increasingly ineffective. Furthermore, there is no effective vaccine on the market. Current experimental vaccines against Chlamydia use a complete protein from the pathogen as the vaccine. The properties of this protein include low solubility, low stability, and the need for detergent solubilization during purification – consequently resulting in a relatively ineffective vaccine. The current invention circumvents these problems by using a mix-and-match approach of combining proteins - a specific sub-region from this same Chlamydia protein and the entire protein from a different Neisseria species. This fusion protein has the potential to be a very effective vaccine against Chlamydia
- Others
-
State Of Development
Protocols for recombinant protein expression from an E. coli vector, purification, and vaccine administration in mice are already available in order to establish proof-of-concept for vaccine design.
Related Materials
Cheng, C.; Pal, S.; Tifrea, D.; Jia, Z.; and de la Maza, L. M. Microbes Infect. 2014, 16, 244-52.
Tech ID/UC Case
27382/2017-205-0
Related Cases
2017-205-0
- *Abstract
-
No vaccines exist against the common sexually-transmitted disease, Chlamydia. The current invention is a novel vaccination formulation wherein fragments from two different microbial proteins, one each from a Chlamydia species and a Neisseria species are fused together. This novel fusion protein is proposed as a robust vaccine to provide protection against Chlamydia.
- *Principal Investigator
-
Name: Luis M. de la Maza
Department:
Name: Guillermo Madico
Department:
Name: Paola Massari
Department:
- Country/Region
- USA
